ClinicalTrials.gg
CompletedNCT05182073Updated Dec 12, 2025

FT576 in Subjects With Multiple Myeloma

A Phase 1 interventional study of FT576 (Allogenic CAR NK cells with BCMA expression) and Cyclophosphamide in Multiple Myeloma and Myeloma, sponsored by Fate Therapeutics. Completed at 14 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-12.

Sponsored by Fate Therapeutics · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Sep 2024, 2 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
31
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 2,168 studies in Multiple Myeloma with a site in United States — 273 open to participants now, 501 under way, 66 of them phase 3. Multiple Myeloma · United States.

Enrollment
1,057th of 1,901
31 · median 36
Started
2021
with 94 others
Phase 1
559 of 2,168
64 open now
Registered
1,779th of 2,168
by date

Among the 2,168 studies in Multiple Myeloma with a site in United States, this one is the 1,057th largest by enrollment of the 1,901 interventional ones that give a count, is one of 95 that started in 2021, is one of 559 in phase 1, and was the 1,779th registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

273 of the 2,168 studies in Multiple Myeloma with a site in United States are open now. Recruiting first, the newest first:

268 more — sign in →

All 273 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,168 studies in Multiple Myeloma with a site in United States, or all of them as a file.
02

Study summary

This is a Phase I dose-finding study of FT576 as monotherapy and in combination with the monoclonal antibody daratumumab in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage.

03

Conditions studied

  • Multiple Myeloma
  • Myeloma

Keywords

  • Multiple Myeloma
  • daratumumab
  • CAR NK cell
  • cellular therapy
  • relapsed/refractory multiple myeloma
  • allogeneic natural killer cells
  • anti-CD38 monoclonal antibody
  • chimeric antigen receptor (CAR)
  • BCMA
  • anti-B-cell maturation antigen (BCMA)
  • natural killer (NK) cell
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  • Abbreviated inclusion criteria:

Diagnosis of r/r MM with by at least one of the following:

  • Serum M-protein ≥1.0 g/dL
  • Urine M-protein ≥200 mg/24 hours
  • Involved serum free light chain level ≥10 mg/dL, with an abnormal kappa-lambda ratio if the serum M-protein \<1.0 g/dL and/or urine M-protein \<200 mg/24 hours
  • Regimens A - A4 only: MM or progressed after ≥3 prior approved therapies, including an IMiD, proteosome inhibitor, and anti-CD38 mAb
  • Regimens B - B4 only: MM relapsed or progressed after ≥2 prior approved therapies, including an IMiD and proteosome inhibitor

Note: for all Regimens, prior BCMA CAR T-cell therapy and BCMA-targeted therapy (e.g., bi-specific engagers or antibody-drug conjugates) is allowed

* Abbreviated exclusion criteria:

Performance Status (ECOG PS) ≥2

Evidence of insufficient hematologic function:

  • ANC \<1000/µL without growth factor support ≤7 days prior to measurement
  • count \<75,000/µL without platelet transfusion ≤72 hours prior to measurement

Evidence of insufficient organ function

  • CrCL \<50 ml/min by or other institutional method
  • T >1.5x , except for Gilbert's syndrome
  • >3x ULN or ALT >3x ULN, unless directly due to underlying
  • O2 sat \<92% on room air

cardiovascular disease:

  • Myocardial infarction within 6 months of first treatment
  • Unstable angina or CHF of Grade 2 or higher
  • Cardiac EF \<40%

Subjects with active central nervous system (CNS) , including . Subjects with prior CNS involvement may be enrolled into the study if effective treatment of their CNS disease was completed at least 3 months prior to Day 1 with no evidence of disease clinically and at least stable findings on relevant CNS imaging.

Non-malignant CNS disease such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease or receipt of medications for these conditions in the 2-year period leading up to study enrollment

Currently receiving or likely to require therapy (e.g., prednisone >5 mg daily) for any reason during the treatment period, with the exception of inhaled .

Clinically significant infections, including:

  • positive by serology
  • positive by serology or PCR
  • positive by serology or PCR

\<6 weeks prior to start of conditioning

Receipt of an allograft organ transplant

Ongoing requirement for systemic graft -versus-host disease therapy

Plasma cell leukemia defined as a plasma cell count >2000/mm\^3

Prior malignancy (other than current indication including any antecedent hematologic disorder) within the 2 years prior to enrollment except for the following: basal or squamous cell carcinomas of the skin, carcinoma in situ of the cervix or breast treated with curative intent, or localized prostate cancer treated with curative intent, or malignancy that, in the opinion of the investigator and Sponsor's Medical Monitor, is considered cured with minimal risk of recurrence within 3 years.

from prior therapies:

- Chemotherapy, or radiation therapy, except for palliative purposes, within 14 days prior to the first dose of FT576 (Day 1) or five half-lives, whichever is shorter; therapy within 30 days prior to the first dose of FT576 study treatment or five half-lives, whichever is shorter; Biologic therapy (e.g., anti-CD38 mAbs or anti-SLAMF7 monoclonal antibodies), including autologous cellular immunotherapy (e.g. CAR-T/ CAR-NK), antibody-drug conjugates or bi-specific immune-cell engaging antibody within 30 days prior to first dose of FT576 (Day 1) or half -lives whichever is shorter. prior allogenic or allogenic CAR-T/CAR-NK within 6 months of first dose of FT576 (Day1).

Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Regimens A-A4

    FT576 single dose monotherapy in subjects with r/r MM

    Drug: FT576 (Allogenic CAR NK cells with BCMA expression) · Drug: Cyclophosphamide · Drug: Fludarabine · Drug: Bendamustine

  • Experimental
    Regimen A1

    FT576 multiple dose monotherapy in subjects with r/r MM

    Drug: FT576 (Allogenic CAR NK cells with BCMA expression) · Drug: Cyclophosphamide · Drug: Fludarabine · Drug: Bendamustine

  • Experimental
    Regimens B-B4

    FT576 single dose in combination with daratumumab in subjects with r/r MM

    Drug: FT576 (Allogenic CAR NK cells with BCMA expression) · Drug: Cyclophosphamide · Drug: Fludarabine · Drug: Daratumumab · Drug: Bendamustine

  • Experimental
    Regimen B1

    FT576 multiple dose in combination with daratumumab in subjects with r/r MM

    Drug: FT576 (Allogenic CAR NK cells with BCMA expression) · Drug: Cyclophosphamide · Drug: Fludarabine · Drug: Daratumumab · Drug: Bendamustine

Interventions

  • DrugFT576 (Allogenic CAR NK cells with BCMA expression)

    Experimental Interventional Therapy: FT576 comprises allogeneic natural killer (NK) cells, derived from a clonal, CD38-knockout, human-induced pluripotent stem cell line (iPSC) that expresses anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR), high-affinity, non-cleavable CD16 (hnCD16), and IL-15/IL-15 receptor fusion protein (IL-15RF).

  • Conditioning Agent

  • Conditioning Agent

  • Anti-CD38 Monoclonal Antibody

    Also known as: Darzalex, Darzalex Faspro

  • Conditioning Agent

    Also known as: Bendeka, Treanda

06

What researchers measure

Primary outcomes

  1. Incidence and nature of DLTs within each dose-escalation cohort to determine the MTD or MAD

    Time frame: Cycle 1 Day -5 to Day 29 for Regimen A and A1; Cycle 1 Day -11 to Day 29 (each cycle is 40 days) for Regimen B and B1

  2. Determine the RP2D which will be based on the overall safety and anti-tumor activity among the dose escalation and dose expansion cohorts

    Time frame: From FPI to LPI's end of Cycle 1 study treatment (End of cycle is Day 29 from Day 1 FT576 infusion)

  3. Incidence, nature, and severity of adverse events

    Time frame: Cycle 1 Day -5 to Day 29 for Regimen A and A1; Cycle 1 Day -11 to Day 29 (each cycle is 40 days) for Regimen B and B1

Secondary outcomes

  1. Objective response rate (ORR)

    Proportion of subjects with a best overall response of sCR, CR, VGPR, or PR, as determined by the investigator according to standard IMWG response criteria

    Time frame: From baseline tumor assessment up to approximately 2 years after last dose of FT576

  2. Duration of response (DOR)

    Duration from the first occurrence of a documented objective response until the time of disease progression or relapse, or death due to progressive disease, as determined by the investigator according to standard IMWG response criteria

    Time frame: Up to 15 years

  3. Progression-free survival (PFS)

    Time from first dose of study treatment to disease progression or relapse, or to the day of death from any cause, as determined by the investigator according to standard IMWG response criteria

    Time frame: Up to 15 years

  4. Relapse-free survival (RFS) from complete response (CR)

    Duration from the start of sCR or CR until the time of relapse from sCR or CR, as determined by the investigator according to standard IMWG response criteria

    Time frame: Up to 15 years

  5. Overall survival (OS)

    Time from first dose of study treatment to death from any cause

    Time frame: Up to 15 years

  6. Pharmacokinetics (PK) of FT576

    Concentration of FT576 in peripheral blood following FT576 administration

    Time frame: From Baseline to PTFU visit of last cycle on the study treatment (End of cycle is Day 29 from Day 1 FT576 infusion of this cycle)

07

Study locations

14 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35205, United States
  • City of Hope
    Duarte, California 91010, United States
  • Scri-Cbci
    Denver, Colorado 80218, United States
  • Medical Oncology Hematology Consultants
    Newark, Delaware 19713, United States
  • Indiana University
    Indianapolis, Indiana 46202, United States
  • University of Minnesota
    Saint Paul, Minnesota 55108, United States
  • Washington University
    St Louis, Missouri 63130, United States
  • Roswell Park
    Buffalo, New York 14263, United States
  • Levine Cancer Institute
    Charlotte, North Carolina 28204, United States
  • Oncology Hematology Care, Inc
    Cincinnati, Ohio 45226, United States
  • Tennessee Oncology - Nashville
    Nashville, Tennessee 37203, United States
  • Texas Oncology-Medical City Dallas
    Dallas, Texas 75230, United States
  • Virginia Oncology Associates
    Norfolk, Virginia 23502, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Sep 2024, 34 months.

Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's 34 months is below that.

Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2021
First posted
Jan 10, 2022
StartActual
Nov 10, 2021
Primary completionActual
Sep 20, 2024
CompletionActual
Oct 18, 2024
Last update
Dec 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05182073
Lead sponsor
Fate Therapeutics
Responsible party
Sponsor
First posted
Jan 10, 2022
Start date
Nov 10, 2021
Primary completion
Sep 20, 2024
Completion
Oct 18, 2024
Last update
Dec 12, 2025

Study contacts

Fate Trial Disclosure
study director · Fate Therapeutics, Inc

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion